Developer docs
API playgroundTry for free, no card

Search company profiles

ARNA Genomics

Full company profile

uuid0003iyx

Namestring
ARNA Genomics
Legal namestring
ARNA Genomics US Incorporated
Websiteurl
arna.bio
Company typeenum
Private
Founded yearint
2013
Descriptiontext

ARNA Genomics US Inc. is a private biotechnology company founded in 2013 (originally as LLC BIOMARKER-RU in Russia) that develops multiomics liquid biopsy tests for early-stage cancer detection. Its flagship product, ARNA Breast, analyzes free-circulating DNA fragments and plasma enzyme activity from a 10ml blood sample to detect six oncospecific genes associated with breast cancer, reporting >90% accuracy in early-stage detection. A proof-of-concept study at Sechenov First Moscow State Medical University on 80 biosamples showed 100% sensitivity, 85-91% specificity, and 100% negative predictive value, with broader blinded studies covering 1,160 patients in Russia and over 600 patients tested with the technology. The underlying platform is patented (applications filed across USA, EU, India, Israel, China, Korea, and Eurasia) and is positioned to extend into tests for lung, liver, pancreatic, colon, ovarian, and prostate cancers.

The company is led by CEO/Founder Egor Melnikov and CSO Anatoly Melnikov, with Dr. Charles R. Cantor (US National Academy of Sciences, founder and former CSO of Sequenom) serving as Scientific Board Chairman and shareholder. ARNA's go-to-market is enterprise-led, targeting hospitals, healthcare systems, and research institutions through direct partnerships (Mayo Clinic, Hoag Memorial Hospital, MNCCTN, Sechenov University, Medical Valley) and clinical trials in the US (New Jersey) and Germany (Mannheim). The commercial model is sale/licensing of in vitro diagnostic tests, with no public pricing disclosed; revenue generation is contingent on securing FDA LDT status in the US and CE-Mark in the EU, both of which are in progress.

ARNA is headquartered in Aliso Viejo, California, with a European office in Forchheim, Germany (opened February 2019 via Medical Valley's Softlanding Program) and a registered office in Dover, Delaware. The company has raised $3.5M in a Series A led by Xploration Capital (September 2020), with Iskra Ventures also listed as an investor, and is supported by Skolkovo Foundation and various Russian state-backed innovation programs. To date, the company is pre-commercial with no disclosed revenue, and its near-term value creation hinges on successful regulatory milestones and clinical validation of ARNA Breast.

Short descriptiontext

ARNA Genomics is a pre-commercial US-headquartered biotech developing multiomics liquid biopsy tests for early cancer detection, with its flagship ARNA Breast test analyzing six oncospecific genes from a blood sample to detect breast cancer at >90% accuracy, targeting hospitals and research institutions ahead of FDA and CE-Mark approvals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, early cancer detection, cell-free DNA analysis, in vitro diagnostics, multiomics biotechnology
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Early Cancer Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Testing Services
TypeOne Time License
Description

Revenue from providing liquid biopsy diagnostic tests for cancer detection, primarily ARNA Breast test for breast cancer screening and early detection.

arna.bio
2In Vitro Diagnostic Tests
TypeOne Time License
Description

Sale of in vitro diagnostic tests for early breast cancer detection based on combined analysis of oncogene fragments in cell-free DNA and plasma enzyme activity.

arna.bio
3Technology Licensing
TypeLicensing Royalties
Description

ARNA technology platform allows development of tests for multiple cancers (lung, liver, pancreas, colon, ovarian, prostate). Future revenue from licensing technology and tests to other markets.

arna.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ARNA Genomics develops and sells multiomics liquid biopsy diagnostic tests for early cancer detection, with its flagship ARNA Breast test analyzing free-circulating DNA in blood plasma to detect 6 oncospecific genes for breast cancer screening. The technology is delivered to healthcare providers, hospitals, and research institutions through clinical trials and medical partnerships, requiring only a 10ml blood sample and achieving >90% accuracy in early-stage cancer detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >90% accuracy for early stage breast cancer detection
+5 more records
Product overview1 text field

ARNA Genomics offers a multiomics liquid biopsy technology platform for early cancer diagnostics. The core product is the ARNA Breast test, which detects breast cancer through analysis of 6 oncospecific genes in free-circulating DNA and plasma enzyme activity. This flagship product achieved >90% accuracy in proof-of-concept studies. The platform was originally developed based on ARNA-1, the company's first general cancer marker. The company is also developing tests for stomach, pancreatic, ovarian, and other cancers using the same technology foundation.

Product and service3 records
1ARNA Breast
CategoryCancer Diagnostic Test
Description

Multiomics liquid biopsy test for early breast cancer detection that analyzes free-circulating DNA (sc-DNA) in blood plasma to detect 6 oncospecific genes and measures plasma enzyme activity. Achieves >90% accuracy in detecting early-stage breast cancer with just 10ml of venous blood. Targeted at healthcare providers, hospitals, and clinical research institutions performing cancer screening.

2ARNA-1
CategoryCancer Diagnostic Test
Description

First cancer marker developed within the ARNA project that determines whether a person has an oncological disease without tumor localization. Serves as the foundational technology for subsequent specific cancer tests including ARNA Breast.

3ARNA Technology Platform (Multi-Cancer Diagnostics)
CategoryDiagnostic Technology Platform
Description

Multiomics liquid biopsy technology platform that enables development of diagnostic tests for multiple cancer types including lung, liver, pancreas, colon, ovarian, and prostate. Features a patented method of amplifying freely circulating DNA directly from blood plasma without prior isolation, combined with analysis of specific gene combinations. Targeted at pharmaceutical and biotechnology partners for licensing and development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Sechenov First Moscow State Medical University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-24
Description

Conducted proof-of-concept study of ARNA Breast test on 80 biosamples. Professor M.I. Sekacheva presented results at Russian Oncological Congress. Study achieved 100% sensitivity and 85% specificity.

arna.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-20
Description

Medical Valley ecosystem partner. Opened European office in Forchheim, Bavaria as part of Softlanding Program. Working towards CE mark registration for ARNA Breast test for entire EU market.

Strategic tierCoreTypeOthersAnnounced on2018-09-10
Description

Dr. Charles R. Cantor joined as shareholder and Board member. World-renowned scientist, member of US National Academy of Sciences, inventor of pulse field gel electrophoresis, author of 400+ articles and 54 US patents.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Medical research collaboration partner in diagnostics development for cancer detection.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Medical partnership for breast cancer diagnostics research and development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership with University Lab Partners for biotechnology research collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership for research and development in biotechnology.

8University of Mannheim
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership with University of Mannheim for biotechnology research.

arna.bio
9MNCCTN (Minnesota North Central Cancer Treatment Group)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cancer research network partnership for clinical research collaboration.

arna.bio
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Supported by Skolkovo Foundation for startup development and innovation in biotechnology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARNA Genomics

Early Cancer Diagnosticsarna.bio

ARNA Genomics is a pre-commercial US-headquartered biotech developing multiomics liquid biopsy tests for early cancer detection, with its flagship ARNA Breast test analyzing six oncospecific genes from a blood sample to detect breast cancer at >90% accuracy, targeting hospitals and research institutions ahead of FDA and CE-Mark approvals.

What ARNA Genomics does

ARNA Genomics US Inc. is a private biotechnology company founded in 2013 (originally as LLC BIOMARKER-RU in Russia) that develops multiomics liquid biopsy tests for early-stage cancer detection. Its flagship product, ARNA Breast, analyzes free-circulating DNA fragments and plasma enzyme activity from a 10ml blood sample to detect six oncospecific genes associated with breast cancer, reporting >90% accuracy in early-stage detection. A proof-of-concept study at Sechenov First Moscow State Medical University on 80 biosamples showed 100% sensitivity, 85-91% specificity, and 100% negative predictive value, with broader blinded studies covering 1,160 patients in Russia and over 600 patients tested with the technology. The underlying platform is patented (applications filed across USA, EU, India, Israel, China, Korea, and Eurasia) and is positioned to extend into tests for lung, liver, pancreatic, colon, ovarian, and prostate cancers.

The company is led by CEO/Founder Egor Melnikov and CSO Anatoly Melnikov, with Dr. Charles R. Cantor (US National Academy of Sciences, founder and former CSO of Sequenom) serving as Scientific Board Chairman and shareholder. ARNA's go-to-market is enterprise-led, targeting hospitals, healthcare systems, and research institutions through direct partnerships (Mayo Clinic, Hoag Memorial Hospital, MNCCTN, Sechenov University, Medical Valley) and clinical trials in the US (New Jersey) and Germany (Mannheim). The commercial model is sale/licensing of in vitro diagnostic tests, with no public pricing disclosed; revenue generation is contingent on securing FDA LDT status in the US and CE-Mark in the EU, both of which are in progress.

ARNA is headquartered in Aliso Viejo, California, with a European office in Forchheim, Germany (opened February 2019 via Medical Valley's Softlanding Program) and a registered office in Dover, Delaware. The company has raised $3.5M in a Series A led by Xploration Capital (September 2020), with Iskra Ventures also listed as an investor, and is supported by Skolkovo Foundation and various Russian state-backed innovation programs. To date, the company is pre-commercial with no disclosed revenue, and its near-term value creation hinges on successful regulatory milestones and clinical validation of ARNA Breast.

ARNA Genomics firmographics

Firmographics
Name
ARNA Genomics
Legal name
ARNA Genomics US Incorporated
Website
https://arna.bio
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
ARNA Genomics is a pre-commercial US-headquartered biotech developing multiomics liquid biopsy tests for early cancer detection, with its flagship ARNA Breast test analyzing six oncospecific genes from a blood sample to detect breast cancer at >90% accuracy, targeting hospitals and research institutions ahead of FDA and CE-Mark approvals.
Ownership category
akta.pro rank

ARNA Genomics industry classification

Industry
Product category
Early Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Early cancer detection
  • Cell-free DNA analysis
  • In vitro diagnostics
  • Multiomics biotechnology

Where ARNA Genomics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices4 records

Markets served

ARNA Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel

Revenue model

  1. Diagnostic Testing Services: Revenue from providing liquid biopsy diagnostic tests for cancer detection, primarily ARNA Breast test for breast cancer screening and early detection.
  2. In Vitro Diagnostic Tests: Sale of in vitro diagnostic tests for early breast cancer detection based on combined analysis of oncogene fragments in cell-free DNA and plasma enzyme activity.
  3. Technology Licensing: ARNA technology platform allows development of tests for multiple cancers (lung, liver, pancreas, colon, ovarian, prostate). Future revenue from licensing technology and tests to other markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

ARNA Genomics product offering

Product offering

Core offering

ARNA Genomics develops and sells multiomics liquid biopsy diagnostic tests for early cancer detection, with its flagship ARNA Breast test analyzing free-circulating DNA in blood plasma to detect 6 oncospecific genes for breast cancer screening. The technology is delivered to healthcare providers, hospitals, and research institutions through clinical trials and medical partnerships, requiring only a 10ml blood sample and achieving >90% accuracy in early-stage cancer detection.

Product overview

ARNA Genomics offers a multiomics liquid biopsy technology platform for early cancer diagnostics. The core product is the ARNA Breast test, which detects breast cancer through analysis of 6 oncospecific genes in free-circulating DNA and plasma enzyme activity. This flagship product achieved >90% accuracy in proof-of-concept studies. The platform was originally developed based on ARNA-1, the company's first general cancer marker. The company is also developing tests for stomach, pancreatic, ovarian, and other cancers using the same technology foundation.

Differentiator

Problem solved

Functional benefit

Products and services

  • ARNA Breast Multiomics liquid biopsy test for early breast cancer detection that analyzes free-circulating DNA (sc-DNA) in blood plasma to detect 6 oncospecific genes and measures plasma enzyme activity. Achieves >90% accuracy in detecting early-stage breast cancer with just 10ml of venous blood. Targeted at healthcare providers, hospitals, and clinical research institutions performing cancer screening.
  • ARNA-1 First cancer marker developed within the ARNA project that determines whether a person has an oncological disease without tumor localization. Serves as the foundational technology for subsequent specific cancer tests including ARNA Breast.
  • ARNA Technology Platform (Multi-Cancer Diagnostics) Multiomics liquid biopsy technology platform that enables development of diagnostic tests for multiple cancer types including lung, liver, pancreas, colon, ovarian, and prostate. Features a patented method of amplifying freely circulating DNA directly from blood plasma without prior isolation, combined with analysis of specific gene combinations. Targeted at pharmaceutical and biotechnology partners for licensing and development.

Quantifiable outcome

  • >90% accuracy for early stage breast cancer detection
  • +5 more outcomes

Companies that use ARNA Genomics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

ARNA Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

ARNA Genomics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, strategic and minor.

  • Sechenov First Moscow State Medical UniversitycoreStrategic or Co-development Partner · 24 September 2019Conducted proof-of-concept study of ARNA Breast test on 80 biosamples. Professor M.I. Sekacheva presented results at Russian Oncological Congress. Study achieved 100% sensitivity and 85% specificity.
  • Medical ValleycoreStrategic or Co-development Partner · 20 February 2019Medical Valley ecosystem partner. Opened European office in Forchheim, Bavaria as part of Softlanding Program. Working towards CE mark registration for ARNA Breast test for entire EU market.
  • Charles R. CantorcoreOthers · 10 September 2018Dr. Charles R. Cantor joined as shareholder and Board member. World-renowned scientist, member of US National Academy of Sciences, inventor of pulse field gel electrophoresis, author of 400+ articles and 54 US patents.
  • Mayo ClinicstrategicStrategic or Co-development PartnerMedical research collaboration partner in diagnostics development for cancer detection.
  • Hoag Memorial Hospital PresbyterianstrategicStrategic or Co-development PartnerMedical partnership for breast cancer diagnostics research and development.
  • University Lab PartnersminorStrategic or Co-development PartnerResearch partnership with University Lab Partners for biotechnology research collaboration.
  • Soka UniversityminorStrategic or Co-development PartnerAcademic partnership for research and development in biotechnology.
  • University of MannheimminorStrategic or Co-development PartnerAcademic partnership with University of Mannheim for biotechnology research.
  • MNCCTN (Minnesota North Central Cancer Treatment Group)minorStrategic or Co-development PartnerCancer research network partnership for clinical research collaboration.
  • Skolkovo FoundationstrategicStrategic or Co-development PartnerSupported by Skolkovo Foundation for startup development and innovation in biotechnology.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

ARNA Genomics competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ARNA Genomics social profiles

Digital presence

ARNA Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARNA Genomics leadership team

Management profile

Number of profiles

Profiles8 records

ARNA Genomics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARNA Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARNA Genomics

What does ARNA Genomics do?

ARNA Genomics develops and sells multiomics liquid biopsy diagnostic tests for early cancer detection, with its flagship ARNA Breast test analyzing free-circulating DNA in blood plasma to detect 6 oncospecific genes for breast cancer screening. The technology is delivered to healthcare providers, hospitals, and research institutions through clinical trials and medical partnerships, requiring only a 10ml blood sample and achieving >90% accuracy in early-stage cancer detection.

Is ARNA Genomics a public or private company?

ARNA Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was ARNA Genomics founded?

ARNA Genomics was founded in 2013. It employs 1 to 10 people.

Where is ARNA Genomics based?

ARNA Genomics is headquartered in San Francisco, United States, in the North America region.

How does ARNA Genomics make money?

Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are in Vitro Diagnostic Tests and technology Licensing.

Does ARNA Genomics have an API?

No public API is recorded for ARNA Genomics.

What industry is ARNA Genomics in?

ARNA Genomics's product category is Early Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals